tegafur has been researched along with Benign Neoplasms in 137 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "As all the anticancer agents, 5-FU leads to several toxicities." | 3.80 | Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. ( Malet-Martino, M; Martino, R, 2002) |
| "A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study." | 3.66 | Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983) |
| "S-1 is an oral anticancer fluoropyrimidine formulation consisting of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate." | 2.78 | Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients. ( Bian, HH; Chen, L; Pu, WY; Wang, H; Wang, J; Zhang, H; Zhu, H; Zhu, MG; Zhuang, ZX, 2013) |
| " To increase the bioavailability of S-1, the administration of S-1 under fasting condition was more effective in the western countries." | 2.77 | Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. ( Hilger, RA; Mende, B; Saito, K; Scheulen, ME; Strumberg, D; Zergebel, C, 2012) |
| "S-1, oxaliplatin and bevacizumab can be administered with acceptable safety and tolerability and without evidence of pharmacokinetic interactions." | 2.76 | Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. ( Chung, KY; Hollywood, E; Saito, K; Saltz, LB; Segal, M; Zergebel, C, 2011) |
| "Patients with advanced solid tumors received single oral doses of S-1 (50 mg) and FT (800 mg) on days 1 and 8 in a randomized crossover fashion." | 2.76 | A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. ( Mendelson, DS; Ravage-Mass, L; Rosen, LS; Saif, MW; Saito, K; Zergebel, C, 2011) |
| "Fifty-eight patients with advanced cancer were assessed." | 2.75 | Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. ( Adachi, M; Fujita, K; Hirose, T; Ishida, H; Miwa, K; Mizuno, K; Nagashima, F; Nishimura, K; Sasaki, Y; Sunakawa, Y; Tanigawara, Y; Yamashita, K, 2010) |
| "S-1 is an oral anticancer agent that combines tegafur (FT) with 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate." | 2.74 | Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas. ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Kawara, K; Kodama, K; Miwa, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W, 2009) |
| " Thus, we prospectively analyzed the effects of the CYP2A6 genotype, plasma level of CDHP, and patient characteristics on the pharmacokinetic (PK) variability of FT and 5-FU." | 2.73 | CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Endo, S; Fujita, K; Ichikawa, W; Kamataki, T; Kawara, K; Kodama, K; Miwa, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W, 2008) |
| "One patient with colorectal cancer experienced a partial response and 9 patients with non-small cell lung, colorectal and gastro-oesophageal junction carcinomas had disease stabilisation lasting 4-26 (median 6) cycles." | 2.71 | Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. ( Algazy, K; Giantonio, B; Hahn, S; Haller, DG; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Thorn, C; Vaughn, D; Veronese, ML; Whitehead, AS, 2004) |
| "The purpose is to determine the effect of food on the bioavailability of S-1, an oral formulation of the 5-fluorouracil (5FU) prodrug Ftorafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), a dihydropyrimidine dehydrogenase inhibitor, and oxonic acid (an inhibitor of 5FU phosphoribosylation in normal gut mucosa) in a molar ratio of 1:0." | 2.71 | The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. ( Beijnen, JH; Fumoleau, P; Giaccone, G; Holwerda, U; Noordhuis, P; Peters, GJ; Schellens, JH; Schornagel, JH; Schrijvers, A; Van Groeningen, CJ; Voorn, D, 2004) |
| " Its combination with uracil in a molar ratio of 1:4 (UFT) increases the 5-FU concentration in tumor cells compared with ftorafur alone." | 2.70 | A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors. ( Beck, J; Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Mayer, F; Schroeder, M; von Pawel, J, 2002) |
| " The pharmacokinetic data presented provide evidence of 5-FU modulation by CDHP." | 2.70 | Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. ( Beard, M; Cohen, SJ; Damle, B; DeCillis, AP; Leichman, CG; Letrent, SP; Meropol, NJ; Proefrock, A; Roedig, B; Yeslow, G, 2002) |
| "Since cancer is incurable in many patients, palliation of symptoms and quality-of-life issues are important aspects of therapy." | 2.69 | UFT/calcium folinate plus weekly paclitaxel for solid tumors. ( Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Mayer, F, 1999) |
| " Plasma pharmacokinetics of 5-FU were linear; at the highest S-1 dose level, 5-FU plasma peak concentrations reached 1 to 2 micromol/L, and the half-life of 5-FU was 3 to 4 hours." | 2.69 | Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. ( de Vries, MJ; Gall, H; Giaccone, G; Hanauske, AR; Noordhuis, P; Peters, GJ; Pinedo, HM; Schornagel, JH; Swart, MS; Turner, SL; van Groeningen, CJ, 2000) |
| " Pharmacokinetic parameters of plasma 5-FU were as follows: Cmax, 128." | 2.69 | Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. ( Aiba, K; Denno, R; Hirata, K; Horikoshi, N; Ishizuka, H; Nakano, Y; Okazaki, M; Sasaki, K; Shirasaka, T; Taguchi, T; Uno, S; Yamada, Y, 1999) |
| "Gemcitabine (Gemzar) is a nucleoside analog increasingly used in the treatment of a variety of solid tumors." | 2.69 | Gemcitabine and UFT plus oral calcium folinate: phase I study. ( Arlauskas, P; Ibrahim, D; Philip, PA; Shields, A; Zalupski, M, 1999) |
| " Pharmacokinetic evaluation showed that single-dose UFT results in maximum plasma levels and an area under the concentration-time curve that increased with escalating UFT doses." | 2.68 | Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. ( Pazdur, R, 1997) |
| " The optimal dosage was considered to be between 17 mg/kg and 24 mg/kg." | 2.65 | [Joint clinical Phase II study of SF-SP]. ( Hanatani, Y; Sato, H; Sato, T, 1984) |
| " Because the oral bioavailability of 5-FU is unpredictable and highly variable, 5-FU is commonly administered intravenously." | 2.52 | Role of ABC transporters in fluoropyrimidine-based chemotherapy response. ( Magdy, T; Nies, AT; Schwab, M; Zanger, UM, 2015) |
| " However, there is a paucity of data from sufficiently powered pharmacokinetic and pharmacodynamic studies to support dosage recommendations in such patients." | 2.50 | Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'. ( Fujita, K; Sasaki, Y, 2014) |
| "5-FU is a core anticancer agent for GI and other malignancies, and infusional 5-FU regimens have been widely utilized." | 2.48 | S-1 as a core anticancer fluoropyrimidine agent. ( Miura, K; Sasaki, I; Shirasaka, T; Yamaue, H, 2012) |
| "Lentinan is a beta(1-3) glucan clarified to have a life prolonging effect in non-operable, recurrent gastric cancer patients in combination with chemotherapy." | 2.43 | [Anticancer immunotherapy with perorally effective lentinan]. ( Hamuro, J, 2005) |
| "The main purpose of the present review article was to shed light on the different 5-fluorouracil (5-FU) prodrugs by underlining their respective pharmacological features in terms of metabolic activation, dihydropyrimidine dehydrogenase inhibition, pharmacokinetic profile and biomodulation ability." | 2.42 | Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. ( Ferrero, JM; François, E; Milano, G, 2004) |
| "The development of anticancer drugs has conventionally focused on intravenous rather than oral regimens." | 2.41 | Novel oral chemotherapy agents. ( Hoff, PM; Pazdur, R; Royce, ME, 2000) |
| " The unpredictable and low oral bioavailability of 5FU initially discouraged this form of treatment." | 2.41 | The oral fluorinated pyrimidines. ( de Bono, JS; Twelves, CJ, 2001) |
| "Tegafur acts as a prodrug of 5-fluorouracil (5-FU), being slowly metabolized by cytochrome P450 to 5-FU." | 2.40 | UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. ( Benner, SE; Canetta, R; Hoff, PM; Pazdur, R, 1998) |
| " When WF is combined with S-1, the prothrombin time-international normalized ratio (PT-INR) and dose adjustment of WF should be closely monitored." | 1.43 | [Evaluation of Drug Interaction between S-1 and Warfarin]. ( Fuse, N; Ikegawa, K; Nomura, H; Saito, S; Suzuki, S; Yamamoto, K, 2016) |
| "Accurate glomerular filtration rate (GFR) evaluation is significant for drug dosing of carboplatin, anticancer drug excreted mainly from kidney." | 1.42 | Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1. ( Ando, Y; Hayashi, M; Kamiya, H; Kobayashi, R; Maruyama, S; Matsuo, S; Nakao, M; Shibata, K; Shimokata, T; Teramachi, H; Tsuchiya, T; Yasuda, Y, 2015) |
| "When epiphora is observed in patients on S-1 therapy, it is necessary to assess optic disorders by an opthalmologist immediately because of suspicion of injury to the cornea and lacrimal duct." | 1.36 | [Optic lesions in patients with epiphora during S-1 therapy]. ( Atsumi, H; Kuze, S; Kyokane, T; Nakamura, H; Shibahara, H; Takamizawa, J, 2010) |
| "These results suggest that the anticancer effect of S-1 can be predicted by performing UrBT 3 h after the initial oral S-1 administration." | 1.36 | Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? ( Asai, S; Ishii, Y; Suzuki, S; Takahashi, Y; Takayama, T, 2010) |
| " Furthermore, 'alternate-day S-1 regimen' may improve the dosing schedule for 5-FU by utilizing its strongly time-dependent mode of action; the former is characterized by the low incidences of myelotoxicity and non-hematologic toxicities (e." | 1.35 | Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. ( Shirasaka, T, 2009) |
| "S-1 is an oral anticancer agent that combines tegafur, a prodrug of 5-fluorouracil (5-FU), and 5-chloro-2,4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase." | 1.35 | Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine). ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Nakayama, H; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K, 2009) |
| "Although it is recommended that the standard S-1 dosage should be based on how large the body surface area is, an on-site setting of the appropriate dosage is often lower than the standard one, depending on the individual's condition and considering possible side effects and so, on." | 1.35 | [Determining S-1 dosage at hospitals prioritizing cancer chemotherapy]. ( Anami, S; Furukawa, H; Hasegawa, K; Imamura, H; Kitada, N; Miyabe, T; Morimoto, S; Morita, S; Tabuse, K; Watari, M; Yamasaki, H, 2008) |
| "Patients with cerebrovascular accidents were excluded." | 1.35 | Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. ( Baehring, JM; Fulbright, RK, 2008) |
| "79 patients(almost gastric cancer), who took drug S-1for the period from November 2000 to February 2006 in Asahi Rosai Hospital, were placed in two groups--a continuous group and a withdrawal group--to investigate and discuss the background factors contributing to the alleviation of digestive medication toxicity." | 1.35 | [Discussion of alleviating digestive medication toxicity in S-1 administered patients--retrospective and comparative study of the health records of continuously-administered patients and withdrawal patients]. ( Fujii, H; Nakao, K, 2009) |
| "In combination with other anticancer drugs such as CPT-11 and taxanes, S-1 exercised synergistic antitumor efficacy not only on 5-FU-sensitive tumors with low expression levels of thymidylate synthase (TS) but also on 5-FU-resistant tumors with originally higher and/or elevated levels of TS expression." | 1.33 | [Antitumor activity and function of S-1, a new oral tegafur-based formulation]. ( Fukushima, M, 2006) |
| " However, the area under the curve from zero to infinity [AUC(INF)] and the terminal elimination half-life (T-HALF) values for R-FT were about 4." | 1.31 | Stereoselective metabolism and pharmacokinetics of tegafur. ( Damle, BD; Kaul, S; Narasimhan, NI, 2001) |
| " These high 5-FU levels disappeared with an apparent elimination half-life (tl/2,beta) of 5." | 1.30 | Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ( Brown, N; Covington, W; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Pazdur, R, 1998) |
| "FT and 5-FU fractions in cancer tissues were found to be higher than those of the patients receiving only 800 mg of Tegafur fine granules as previously reported." | 1.27 | [UFT concentration in various tissues from cancer patients]. ( Bekki, E; Hashimoto, I; Kasai, Y; Mikami, J; Nakamura, T; Nakanishi, Y; Nishi, H; Nishindai, H; Sawada, Y; Yoshimoto, M, 1983) |
| " Pharmacokinetic study after single oral administration of 300 to 1200 mg of UFT-E was carried out in cancer patients measuring tagafur, uracil and 5-FU levels in serum, normal tissue and tumor tissue using HPLC and GC-mass." | 1.27 | [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients]. ( Fujii, S; Hoshino, A; Kamiya, O; Kimura, K; Kojima, T; Nagata, K; Ohara, K; Sugihara, T; Suzuki, M; Yamada, M, 1983) |
| "CR was observed in one case of breast cancer, and PR in 29 cases." | 1.27 | [Cooperative phase II study of spansule tegafur (SF-SP)]. ( Taguchi, T, 1984) |
| " In these 5 cases the daily dosage was 800 mg, and the median duration of PR was 51 days." | 1.27 | [Study of chemotherapy in the field of internal medicine--clinical experience with SF-SP]. ( Fujisawa, T; Imamura, Y; Irie, K; Mizogami, H; Nakamura, T; Nishimura, S; Sawada, Y; Yasutake, K; Yoshida, M; Yoshimura, Y, 1986) |
| "Other response rates were spleen cancer 25%, gallbladder cancer 25%, liver cancer 19." | 1.27 | [Report on nationwide pooled data and cohort investigation in UFT phase II study]. ( Kimura, K; Ota, K; Taguchi, T, 1987) |
| " Although average values of the skin reaction after dosing were slightly lower compared to those before dosing in group B, sensitization was effective." | 1.27 | [Study on the preoperative adjuvant therapy of cancer--relation between serum and tumor tissue levels of UFT and OK-432 after administration, and skin reactions to Su-polysaccharide (Su-Ps)]. ( Ishikawa, M; Kumazawa, H; Rei, S; Saito, H, 1987) |
| "FD-1, a new anticancer drug, is a fluorinated pyrimidine derivative that has shown less acute toxicity than 5-FU and FT-207, and higher antitumor activity than FT-207 in Ehrlich carcinoma, S-180, AH-130, Yoshida sarcoma, and Walker 256." | 1.26 | Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1). ( Taguchi, T, 1980) |
| "These xenografts were 1 line of rectal cancer (H-26), two lines of gastric cancer (H-08 and H-22), and 1 line of breast cancer (H-62)." | 1.26 | Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient. ( Fujita, M; Hayata, S; Taguchi, T, 1980) |
| "Fifteen cases with advanced cancer were treated with UFD-1 (mixture of FD-1 and uracil under molar ratio of 1: 20) in a daily dose of 300 mg of FD-1." | 1.26 | [Clinical experiences with UFD-1]. ( Furue, H, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (27.01) | 18.7374 |
| 1990's | 24 (17.52) | 18.2507 |
| 2000's | 38 (27.74) | 29.6817 |
| 2010's | 35 (25.55) | 24.3611 |
| 2020's | 3 (2.19) | 2.80 |
| Authors | Studies |
|---|---|
| Wörmann, B | 1 |
| Bokemeyer, C | 4 |
| Burmeister, T | 1 |
| Köhne, CH | 1 |
| Schwab, M | 3 |
| Arnold, D | 1 |
| Blohmer, JU | 1 |
| Borner, M | 1 |
| Brucker, S | 1 |
| Cascorbi, I | 1 |
| Decker, T | 1 |
| de Wit, M | 1 |
| Dietz, A | 1 |
| Einsele, H | 1 |
| Eisterer, W | 1 |
| Folprecht, G | 1 |
| Hilbe, W | 1 |
| Hoffmann, J | 1 |
| Knauf, W | 1 |
| Kunzmann, V | 1 |
| Largiadèr, CR | 2 |
| Lorenzen, S | 1 |
| Lüftner, D | 1 |
| Moehler, M | 1 |
| Nöthen, MM | 1 |
| Pox, C | 1 |
| Reinacher-Schick, A | 1 |
| Scharl, A | 1 |
| Schlegelberger, B | 1 |
| Seufferlein, T | 1 |
| Sinn, M | 1 |
| Stroth, M | 1 |
| Tamm, I | 1 |
| Trümper, L | 1 |
| Wilhelm, M | 1 |
| Wöll, E | 1 |
| Hofheinz, RD | 1 |
| Zhang, Z | 1 |
| Li, A | 1 |
| Min, X | 1 |
| Zhang, Q | 1 |
| Yang, J | 1 |
| Chen, G | 1 |
| Zou, M | 1 |
| Sun, W | 3 |
| Cheng, G | 1 |
| Takeuchi, M | 1 |
| Imamura, CK | 1 |
| Booka, E | 1 |
| Takeuchi, H | 1 |
| Mizukami, T | 1 |
| Kawakami, T | 1 |
| Funakoshi, T | 1 |
| Wakuda, K | 1 |
| Aoki, Y | 1 |
| Hamamoto, Y | 1 |
| Kitago, M | 1 |
| Kawakubo, H | 1 |
| Boku, N | 1 |
| Tanigawara, Y | 2 |
| Kitagawa, Y | 1 |
| Moriya, K | 1 |
| Shimizu, H | 1 |
| Handa, S | 1 |
| Sasaki, T | 2 |
| Sasaki, Y | 6 |
| Takahashi, H | 2 |
| Nakamura, S | 1 |
| Yoshida, H | 1 |
| Kato, Y | 1 |
| Okuda, Y | 1 |
| Mikame, Y | 1 |
| Watano, R | 1 |
| Masubuchi, M | 1 |
| Nishijima, H | 1 |
| Shinada, M | 1 |
| Mori, M | 1 |
| Fujii, H | 2 |
| Sudoh, T | 1 |
| Akune, Y | 1 |
| Yamada, M | 2 |
| Shigeyasu, C | 1 |
| Milano, G | 2 |
| Fujita, K | 5 |
| Takahashi, N | 1 |
| Kobayashi, M | 1 |
| Ogura, J | 1 |
| Yamaguchi, H | 1 |
| Satoh, T | 1 |
| Watanabe, K | 1 |
| Iseki, K | 1 |
| Nies, AT | 1 |
| Magdy, T | 1 |
| Zanger, UM | 2 |
| Kase, S | 1 |
| Shibata, K | 1 |
| Yasuda, Y | 1 |
| Kobayashi, R | 1 |
| Ando, Y | 4 |
| Shimokata, T | 1 |
| Kamiya, H | 1 |
| Hayashi, M | 1 |
| Maruyama, S | 1 |
| Matsuo, S | 1 |
| Nakao, M | 1 |
| Tsuchiya, T | 1 |
| Teramachi, H | 1 |
| Abdel-Rahman, O | 2 |
| ElHalawani, H | 2 |
| Essam-Eldin, S | 2 |
| Meulendijks, D | 1 |
| Henricks, LM | 1 |
| Sonke, GS | 1 |
| Deenen, MJ | 2 |
| Froehlich, TK | 1 |
| Amstutz, U | 1 |
| Jennings, BA | 1 |
| Marinaki, AM | 1 |
| Sanderson, JD | 1 |
| Kleibl, Z | 1 |
| Kleiblova, P | 1 |
| Palles, C | 1 |
| Tomlinson, I | 1 |
| Gross, E | 1 |
| van Kuilenburg, AB | 3 |
| Punt, CJ | 1 |
| Koopman, M | 1 |
| Beijnen, JH | 3 |
| Cats, A | 2 |
| Schellens, JH | 3 |
| Yamamoto, K | 1 |
| Suzuki, S | 2 |
| Ikegawa, K | 1 |
| Nomura, H | 1 |
| Fuse, N | 1 |
| Saito, S | 1 |
| Maeda, M | 1 |
| Saito, Y | 1 |
| Makino, Y | 1 |
| Iwase, H | 1 |
| Hayashi, Y | 1 |
| Yamada, R | 1 |
| Sotozono, C | 1 |
| Nakamura, T | 3 |
| Nishida, A | 1 |
| Nakanishi, S | 1 |
| Hirabatake, M | 1 |
| Tsuji, A | 1 |
| Kurimoto, Y | 1 |
| Kwakman, JJM | 1 |
| Baars, A | 1 |
| Boot, H | 1 |
| Pruijt, JFM | 1 |
| Winther, SB | 1 |
| Pfeiffer, P | 1 |
| Punt, CJA | 1 |
| Kojima, T | 3 |
| Matsui, T | 1 |
| Uemura, T | 1 |
| Fujimitsu, Y | 1 |
| Kure, N | 1 |
| Mochizuki, Y | 1 |
| Kojima, H | 1 |
| Shirasaka, T | 6 |
| Ichikawa, W | 3 |
| Yamamoto, W | 3 |
| Endo, H | 3 |
| Nagashima, F | 4 |
| Tanaka, R | 3 |
| Miya, T | 3 |
| Araki, K | 3 |
| Kodama, K | 2 |
| Sunakawa, Y | 4 |
| Narabayashi, M | 3 |
| Miwa, K | 4 |
| Akiyama, Y | 3 |
| Kawara, K | 3 |
| Saif, MW | 2 |
| Syrigos, KN | 1 |
| Katirtzoglou, NA | 1 |
| Nakao, K | 1 |
| Nakayama, H | 1 |
| Yamashita, K | 2 |
| Mizuno, K | 2 |
| Ishida, H | 2 |
| Hirose, T | 2 |
| Hamada, C | 1 |
| Ishii, Y | 1 |
| Takahashi, Y | 1 |
| Takayama, T | 1 |
| Asai, S | 1 |
| Matsumoto, Y | 1 |
| Dogru, M | 1 |
| Sato, EA | 1 |
| Ibrahim, OM | 1 |
| Tatematsu, Y | 1 |
| Ogawa, Y | 1 |
| Tsubota, K | 1 |
| Nishimura, K | 1 |
| Adachi, M | 1 |
| Kihara, K | 1 |
| Kamimura, H | 1 |
| Isayama, H | 1 |
| Fujii, Y | 1 |
| Iino, Y | 1 |
| Shibahara, H | 1 |
| Kuze, S | 1 |
| Kyokane, T | 1 |
| Takamizawa, J | 1 |
| Nakamura, H | 1 |
| Atsumi, H | 1 |
| Fukushima, M | 2 |
| Sakamoto, K | 1 |
| Sakata, M | 1 |
| Nakagawa, F | 1 |
| Saito, H | 2 |
| Sakata, Y | 1 |
| Chuah, B | 1 |
| Goh, BC | 1 |
| Lee, SC | 1 |
| Soong, R | 1 |
| Lau, F | 1 |
| Mulay, M | 1 |
| Dinolfo, M | 1 |
| Lim, SE | 1 |
| Soo, R | 1 |
| Furuie, T | 1 |
| Saito, K | 4 |
| Zergebel, C | 4 |
| Rosen, LS | 2 |
| Zohar, S | 1 |
| Katsahian, S | 1 |
| O'Quigley, J | 1 |
| Kitamura, H | 1 |
| Miyanaga, T | 1 |
| Shin, H | 1 |
| Fujita, M | 2 |
| Miyazaki, M | 1 |
| Yagi, D | 1 |
| Ito, H | 1 |
| Asaumi, Y | 1 |
| Hirano, Y | 1 |
| Hayashida, Y | 1 |
| Maeda, K | 1 |
| Ota, K | 4 |
| Hayashi, H | 1 |
| Douden, K | 1 |
| Hattori, M | 1 |
| Hashidume, Y | 1 |
| Ravage-Mass, L | 1 |
| Mendelson, DS | 1 |
| Shah, SK | 1 |
| Walker, PA | 1 |
| Moore-Olufemi, SD | 1 |
| Sundaresan, A | 1 |
| Kulkarni, AD | 1 |
| Andrassy, RJ | 1 |
| Nakamura, K | 1 |
| Abu Lila, AS | 1 |
| Matsunaga, M | 1 |
| Doi, Y | 1 |
| Ishida, T | 1 |
| Kiwada, H | 1 |
| Hu, QD | 1 |
| Fan, H | 1 |
| Lou, WJ | 1 |
| Wang, QQ | 1 |
| Tang, GP | 1 |
| Chung, KY | 1 |
| Hollywood, E | 1 |
| Segal, M | 1 |
| Saltz, LB | 1 |
| Scheulen, ME | 1 |
| Hilger, RA | 1 |
| Mende, B | 1 |
| Strumberg, D | 1 |
| Miura, K | 1 |
| Yamaue, H | 1 |
| Sasaki, I | 1 |
| Hirashima, Y | 1 |
| Shirao, K | 1 |
| Mandigers, CM | 1 |
| Soesan, M | 1 |
| Terpstra, WE | 1 |
| Zhuang, ZX | 1 |
| Zhu, H | 1 |
| Wang, J | 1 |
| Zhu, MG | 1 |
| Wang, H | 1 |
| Pu, WY | 1 |
| Bian, HH | 1 |
| Chen, L | 1 |
| Zhang, H | 1 |
| Cohen, SJ | 1 |
| Leichman, CG | 1 |
| Yeslow, G | 1 |
| Beard, M | 1 |
| Proefrock, A | 1 |
| Roedig, B | 1 |
| Damle, B | 1 |
| Letrent, SP | 1 |
| DeCillis, AP | 1 |
| Meropol, NJ | 2 |
| Sugimura, T | 1 |
| Malet-Martino, M | 1 |
| Martino, R | 1 |
| Peters, GJ | 4 |
| Noordhuis, P | 3 |
| Schornagel, JH | 3 |
| Gall, H | 2 |
| Turner, SL | 2 |
| Swart, MS | 2 |
| Voorn, D | 2 |
| Van Gennip, AH | 2 |
| Wanders, J | 1 |
| Holwerda, U | 2 |
| Smid, K | 1 |
| Giaccone, G | 3 |
| Fumoleau, P | 2 |
| Van Groeningen, CJ | 3 |
| Veronese, ML | 1 |
| Stevenson, JP | 2 |
| Redlinger, M | 2 |
| Algazy, K | 1 |
| Giantonio, B | 1 |
| Hahn, S | 1 |
| Vaughn, D | 1 |
| Thorn, C | 1 |
| Whitehead, AS | 1 |
| Haller, DG | 1 |
| O'Dwyer, PJ | 2 |
| Schrijvers, A | 1 |
| Ferrero, JM | 1 |
| François, E | 1 |
| Rustum, YM | 1 |
| Hamuro, J | 1 |
| Taguchi, T | 13 |
| Hirata, K | 2 |
| Horikoshi, N | 2 |
| Tominaga, K | 1 |
| Sohma, K | 1 |
| Yamaguchi, K | 1 |
| Okazaki, M | 2 |
| Furuhata, T | 1 |
| Sasaki, K | 2 |
| Nakano, Y | 2 |
| Ishizuka, H | 2 |
| Yamada, Y | 2 |
| Uno, S | 2 |
| Yamamitsu, S | 1 |
| El-Rayes, BF | 1 |
| Zalupski, M | 2 |
| Shields, AF | 1 |
| Manza, SG | 1 |
| LoRusso, P | 1 |
| Philip, PA | 2 |
| Baehring, JM | 1 |
| Fulbright, RK | 1 |
| Endo, S | 1 |
| Kamataki, T | 1 |
| Morimoto, S | 1 |
| Kitada, N | 1 |
| Anami, S | 1 |
| Miyabe, T | 1 |
| Morita, S | 1 |
| Watari, M | 1 |
| Yamasaki, H | 1 |
| Imamura, H | 1 |
| Furukawa, H | 1 |
| Hasegawa, K | 3 |
| Tabuse, K | 1 |
| Kimura, K | 5 |
| Suga, S | 2 |
| Kasai, Y | 1 |
| Nakanishi, Y | 1 |
| Nishi, H | 1 |
| Nishindai, H | 1 |
| Yoshimoto, M | 1 |
| Hashimoto, I | 1 |
| Sawada, Y | 2 |
| Mikami, J | 1 |
| Bekki, E | 1 |
| Kamiya, O | 1 |
| Hoshino, A | 1 |
| Ohara, K | 1 |
| Nagata, K | 1 |
| Sugihara, T | 1 |
| Suzuki, M | 1 |
| Fujii, S | 1 |
| Ansfield, FJ | 1 |
| Kallas, GJ | 1 |
| Singson, JP | 1 |
| Sato, T | 1 |
| Sato, H | 1 |
| Hanatani, Y | 1 |
| Fujita, H | 2 |
| Furue, H | 3 |
| Tanneberger, S | 1 |
| Müller, U | 1 |
| Marunaka, T | 1 |
| Umeno, Y | 1 |
| Minami, Y | 1 |
| Hayata, S | 1 |
| Friedman, MA | 1 |
| Ignoffo, RJ | 1 |
| Au, JL | 2 |
| Sadée, W | 2 |
| Sakurai, Y | 1 |
| Matsuoka, S | 1 |
| Maezawa, S | 1 |
| Sakuma, M | 1 |
| Ohira, S | 1 |
| Wakui, A | 1 |
| Saito, T | 2 |
| Tschiersch, B | 1 |
| Kikuchi, K | 1 |
| Majima, S | 1 |
| Murakami, M | 1 |
| Kurihara, M | 3 |
| Eckardt, J | 1 |
| Eckhardt, G | 1 |
| Villalona-Calero, M | 1 |
| Drengler, R | 1 |
| Von Hoff, D | 1 |
| Pazdur, R | 6 |
| Lassere, Y | 2 |
| Diaz-Canton, E | 1 |
| Bready, B | 1 |
| Ho, DH | 2 |
| Inuyama, Y | 1 |
| Kanamaru, R | 1 |
| Akazawa, S | 1 |
| Niitani, H | 1 |
| Ariyoshi, Y | 1 |
| Takai, S | 1 |
| Shimoyama, T | 1 |
| Toge, T | 1 |
| Takashima, S | 1 |
| Sugimachi, K | 1 |
| Hara, Y | 1 |
| Tsukagoshi, S | 1 |
| Nakao, I | 1 |
| Covington, W | 1 |
| Brown, N | 1 |
| Huo, YY | 1 |
| Kuritani, J | 1 |
| Hoff, PM | 4 |
| Benner, SE | 1 |
| Canetta, R | 1 |
| DeMario, MD | 1 |
| Ratain, MJ | 1 |
| Vogelzang, NJ | 1 |
| Mani, S | 1 |
| Vokes, EE | 1 |
| Fleming, GF | 1 |
| Melton, K | 1 |
| Johnson, S | 1 |
| Benner, S | 1 |
| Lebwohl, D | 1 |
| González Barón, M | 1 |
| Diasio, RB | 1 |
| Hartmann, JT | 3 |
| Kollmannsberger, C | 1 |
| Mayer, F | 3 |
| Kanz, L | 3 |
| Ibrahim, D | 1 |
| Arlauskas, P | 1 |
| Shields, A | 1 |
| Aiba, K | 1 |
| Denno, R | 1 |
| Blanke, CD | 1 |
| Teng, M | 1 |
| Choy, H | 1 |
| Muto, Y | 1 |
| Takebuchi, K | 1 |
| Watanabe, M | 1 |
| Sakonji, M | 1 |
| Matsukawa, M | 1 |
| de Vries, MJ | 1 |
| Pinedo, HM | 1 |
| Hanauske, AR | 1 |
| Böhlke, I | 1 |
| Von Pawel, J | 2 |
| Derigs, G | 1 |
| Schröder, M | 1 |
| Gojo, I | 1 |
| Tkaczuk, KH | 1 |
| Haller, D | 1 |
| Lewis, NL | 1 |
| Royce, ME | 1 |
| Wada, H | 1 |
| Saad, ED | 1 |
| Minsky, BD | 1 |
| de Bono, JS | 1 |
| Twelves, CJ | 1 |
| Kubota, T | 1 |
| Stroomer, AE | 1 |
| Damle, BD | 1 |
| Narasimhan, NI | 1 |
| Kaul, S | 1 |
| Beck, J | 1 |
| Schroeder, M | 1 |
| Boehlke, I | 1 |
| Carter, SK | 1 |
| Slavik, M | 1 |
| Voznyĭ, EK | 1 |
| Borisov, VN | 1 |
| Soejima, S | 1 |
| Golubeva, VA | 1 |
| Osipov, NE | 1 |
| Bukharova, IK | 1 |
| Blokhina, NG | 1 |
| Smolianskaia, AZ | 1 |
| Aledseev, VM | 1 |
| Sokolova, VD | 1 |
| Sawai, K | 1 |
| Sonoda, Y | 1 |
| Ohkuma, S | 1 |
| Misawa, S | 1 |
| Takino, T | 1 |
| Hall, SW | 1 |
| Valdivieso, M | 1 |
| Benjamin, RS | 1 |
| Shioda, R | 1 |
| Nomura, Y | 1 |
| Kato, T | 1 |
| Hikasa, Y | 1 |
| Sokova, OI | 1 |
| Volgareva, GM | 1 |
| Blokhin, NN | 1 |
| Chihara, G | 1 |
| Kamano, T | 1 |
| Irie, K | 1 |
| Yasutake, K | 1 |
| Imamura, Y | 1 |
| Yoshimura, Y | 1 |
| Yoshida, M | 1 |
| Fujisawa, T | 1 |
| Nishimura, S | 1 |
| Mizogami, H | 1 |
| Wada, T | 1 |
| Nishide, T | 1 |
| Hatayama, K | 1 |
| Chang, SW | 1 |
| Tatsuta, M | 1 |
| Yasutomi, M | 1 |
| Kumazawa, H | 1 |
| Ishikawa, M | 1 |
| Rei, S | 1 |
| Yamamoto, Y | 1 |
| Amano, T | 1 |
| Imada, T | 1 |
| Tamura, S | 1 |
| Abe, M | 1 |
| Matsumoto, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced Non-squamous Non-small Cell Lung Cancer[NCT03700333] | Phase 3 | 120 participants (Anticipated) | Interventional | 2018-10-20 | Not yet recruiting | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin[NCT00003925] | Phase 1 | 36 participants (Anticipated) | Interventional | 1998-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
41 reviews available for tegafur and Benign Neoplasms
| Article | Year |
|---|---|
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.
Topics: Antimetabolites, Antineoplastic; Austria; Capecitabine; Consensus; Dihydrouracil Dehydrogenase (NADP | 2020 |
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationsh | 2014 |
Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassett | 2015 |
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; I | 2016 |
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gas | 2015 |
S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2016 |
S-1: a promising new oral fluoropyrimidine derivative.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 2009 |
The role of meta-analysis in cancer clinical trials.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Humans; Meta-Analysis as Topic; Neoplasms; Rectal Neopl | 2009 |
An evidence-based review of a Lentinula edodes mushroom extract as complementary therapy in the surgical oncology patient.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2011 |
S-1 as a core anticancer fluoropyrimidine agent.
Topics: Absorption; Administration, Oral; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administra | 2012 |
[The principles of cancer treatment--changes in chemotherapy].
Topics: ADP Ribose Transferases; Animals; Antineoplastic Agents; Benzamides; Cisplatin; Drug Combinations; F | 2002 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neop | 2002 |
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Thymidylate synthase: a critical target in cancer therapy?
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Proliferation; Clinical Tr | 2004 |
[Anticancer immunotherapy with perorally effective lentinan].
Topics: Adjuvants, Immunologic; Administration, Oral; Antineoplastic Agents; beta-Glucans; Drug Combinations | 2005 |
[Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinatio | 2006 |
[Pharmacokinetics of S-1].
Topics: Administration, Oral; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2006 |
The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil.
Topics: Animals; Biotransformation; Fluorouracil; Humans; Kinetics; Neoplasms; Tegafur | 1981 |
Studies of analogs of fluorinated pyrimidine in Japan.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluorouraci | 1981 |
[Metabolic modulation as a method in tumor chemotherapy].
Topics: Antineoplastic Agents; Cytarabine; Fluorouracil; Humans; Methotrexate; Neoplasms; Tegafur; Thymidine | 1982 |
Clinical experience with UFT in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Japan; Neoplasms; | 1993 |
[Development of fluorinated pyrimidines in Japan].
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorode | 1993 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1995 |
Modulation of 5-FU and its related compounds.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; | 1997 |
Experience with UFT in Japan.
Topics: Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug | 1997 |
UFT: biochemical modulation for 5-fluorouracil (5-FU).
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as | 1997 |
UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 1998 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1998 |
Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological Availabi | 1999 |
The University of Texas M. D. Anderson Cancer Center Orzel/UFT Investigators' Workshop and Consensus Conference. October 15-18, 1998. Proceedings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasms; Tegafur; Uracil | 1999 |
The role of UFT in combined-modality therapy.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 1999 |
Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2000 |
The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2000 |
Other fluorinated pyrimidines in the treatment of solid tumors.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Combinations; Fluorouracil; Humans; | 2001 |
UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinic | 2001 |
The oral fluorinated pyrimidines.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransfor | 2001 |
[5-fluorouracil and dihydropyrimidine dehydrogenase].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2001 |
Investigational drugs under study by the United States National Cancer Institute.
Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Ant | 1976 |
Recent progress in immunopharmacology and therapeutic effects of polysaccharides.
Topics: Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Animals; Drug Screening Assays, Antitumo | 1992 |
30 trials available for tegafur and Benign Neoplasms
| Article | Year |
|---|---|
Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application.
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female; | 2021 |
Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Bo | 2009 |
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Cu | 2010 |
A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dihydrouracil Dehyd | 2011 |
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2011 |
Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biological Av | 2012 |
Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cross-Ov | 2013 |
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Cu | 2002 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neop | 2002 |
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Dose-Respon | 2003 |
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dos | 2004 |
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2004 |
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Fem | 2007 |
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Asia | 2008 |
[Joint clinical Phase II study of SF-SP].
Topics: Clinical Trials as Topic; Colonic Neoplasms; Delayed-Action Preparations; Drug Evaluation; Female; F | 1984 |
Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Fem | 1996 |
Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Ph | 1997 |
[Phase I study of S-1. S-1 Study Group].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1997 |
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1999 |
UFT/calcium folinate plus weekly paclitaxel for solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 1999 |
Gemcitabine and UFT plus oral calcium folinate: phase I study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1999 |
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Drug Combinati | 1999 |
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Human | 2000 |
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Re | 2000 |
A phase I study of paclitaxel, UFT, and leucovorin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Rel | 2000 |
Irinotecan and UFT/leucovorin in patients with advanced cancers.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Rel | 2002 |
Recent progress in immunopharmacology and therapeutic effects of polysaccharides.
Topics: Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Animals; Drug Screening Assays, Antitumo | 1992 |
[Clinical results of UFT enteric-coated granule therapy under cooperative study (phase II study). Tokyo Cancer Chemotherapy Cooperative Study Group].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 1990 |
[A comparative clinical trial with tegafur plus lentinan treatment at two different doses in advanced cancer].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Lentinan; Middle Aged; Neoplasms; Polysaccha | 1987 |
68 other studies available for tegafur and Benign Neoplasms
| Article | Year |
|---|---|
An ROS-sensitive tegafur-PpIX-heterodimer-loaded
Topics: Hydrogels; Neoplasms; Photochemotherapy; Protoporphyrins; Reactive Oxygen Species; Tegafur | 2021 |
Incidence of Ophthalmic Disorders in Patients Treated with the Antineoplastic Agent S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Eye Diseases; Female; Humans; Incidence; M | 2017 |
[A Retrospective Investigation of Lacrimation in Patients Treated with S-1].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; | 2018 |
Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chromatograph | 2018 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2019 |
Immunoprotective effect of epigallocatechin-3-gallate on oral anticancer drug-induced α-defensin reduction in Caco-2 cells.
Topics: alpha-Defensins; Antimetabolites, Antineoplastic; Antioxidants; Caco-2 Cells; Catechin; Herb-Drug In | 2014 |
[Corneal epithelial disorder, lacrimal drainage obstruction, and conjunctivitis].
Topics: Antimetabolites, Antineoplastic; Conjunctivitis; Corneal Diseases; Drug Combinations; Epithelial Cel | 2015 |
Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carbop | 2015 |
[Evaluation of Drug Interaction between S-1 and Warfarin].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Drug Combinations; Drug In | 2016 |
[The Importance of Medication History Management by Hospital and Community Pharmacists for Oral Anticancer Drug S-1(Tegafur/Gimeracil/Oteracil Potassium)--A Retrospective Study].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Community Pha | 2016 |
Predictive factors for ocular complications caused by anticancer drug S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Conjunctivitis; Corneal Diseases; D | 2016 |
Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Denmark; Drug Combinations; Drug Substitution; Female; | 2017 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Mo | 2008 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; History, 20th Century; Hi | 2009 |
[Discussion of alleviating digestive medication toxicity in S-1 administered patients--retrospective and comparative study of the health records of continuously-administered patients and withdrawal patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Digestive System Diseases; Drug Combinations; Humans | 2009 |
Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; | 2009 |
Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon H | 2010 |
S-1 induces meibomian gland dysfunction.
Topics: Aged; Antimetabolites, Antineoplastic; Corneal Diseases; Drug Combinations; Dry Eye Syndromes; Eyeli | 2010 |
[Suppression of renin-angiotensin system and cancer therapy (discussion)].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; B | 2010 |
[Optic lesions in patients with epiphora during S-1 therapy].
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Eye Diseases; Female; Humans; Lacrimal Apparatus | 2010 |
Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy | 2010 |
Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asia, | 2011 |
An approach to meta-analysis of dose-finding studies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Computer S | 2011 |
[Investigation of epiphora following S-1 therapy].
Topics: Aged; Drug Combinations; Female; Humans; Lacrimal Apparatus Diseases; Male; Middle Aged; Neoplasms; | 2011 |
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Combined Modality Therap | 2011 |
Polyethylenimine-cyclodextrin-tegafur conjugate shows anti-cancer activity and a potential for gene delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; COS Cells; Cyclodextrins; DNA; Drug Combinations; | 2011 |
[Predicting drug efficacy-fluorinated pyrimidines (fluorouracil, S-1 and capecitabine)].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Human | 2012 |
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency | 2012 |
[Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Edema; Capecitabine; Dementia, Vascular; Deoxycytid | 2008 |
[Determining S-1 dosage at hospitals prioritizing cancer chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Response Relat | 2008 |
[Pharmacological and pharmacodynamic aspects of cancer chemotherapy, with special reference to 5-fluorouracil and its derivatives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Floxuridine; Fluorouracil; Humans | 1982 |
[UFT concentration in various tissues from cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1983 |
[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Pr | 1983 |
[Cooperative phase II study of spansule tegafur (SF-SP)].
Topics: Administration, Oral; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Delayed-Action Preparatio | 1984 |
Phase I-II studies of oral tegafur (ftorafur).
Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1983 |
[UFT].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combina | 1984 |
[Pharmacokinetics of fluoropyrimidines].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ehrlich Tumor; Fluorouracil; Hum | 1984 |
[Fluorinated pyrimidines--administration methods].
Topics: Drug Administration Schedule; Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Tegafur | 1984 |
[10 years' use of ftorafur in tumor chemotherapy at the Robert Rössle Institute. A retrospective analysis from the clinical-toxologic point of view].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Adm | 1984 |
Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1).
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations; Dogs; Drug Evalu | 1980 |
Quantitative determination of 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione and its metabolites in visceral tissues by high-performance liquid chromatography and gas chromatography-mass fragmentography.
Topics: Animals; Chromatography, High Pressure Liquid; Fluorouracil; Gas Chromatography-Mass Spectrometry; N | 1980 |
Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient.
Topics: Adult; Animals; Cytarabine; Drug Resistance; Drug Therapy, Combination; Female; Fluorouracil; Humans | 1980 |
A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958).
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; | 1980 |
Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients.
Topics: Adult; Aged; Biotransformation; Cytochrome P-450 Enzyme System; Esophageal Neoplasms; Female; Fluoro | 1981 |
[Clinical experiences with UFD-1].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combination | 1982 |
[Clinical survey on cardiotoxicity of tegafur (FT-207)--compilation of a nationwide survey].
Topics: Administration, Oral; Adult; Aged; Electrocardiography; Female; Fluorouracil; Heart; Humans; Infusio | 1982 |
UFT: East meets West in drug development.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; | 1997 |
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1998 |
[Consideration of cancer home chemotherapy with cooperation between hospital and clinic].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cooperative Behavior; Drug Administration | 1999 |
[Oral chemotherapeutic agents: the roles in cancer chemotherapy].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Co | 1999 |
Simultaneous determination of F-beta-alanine and beta-alanine in plasma and urine with dual-column reversed-phase high-performance liquid chromatography.
Topics: beta-Alanine; Chromatography, High Pressure Liquid; Humans; Neoplasms; Reproducibility of Results; S | 2001 |
Stereoselective metabolism and pharmacokinetics of tegafur.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoplasms; Stereoisomerism; Tegafur | 2001 |
[Present-day chemotherapy in malignant tumors].
Topics: Bleomycin; Carubicin; Humans; Neoplasms; Tegafur | 1978 |
[Long-term oral administration of anticancer drug (author's transl)].
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Fluorouracil; Humans; Immunoglobulins; | 1979 |
[Therapeutic effect of ftorafur].
Topics: Adenocarcinoma; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Fluorouracil; Mammary Gland | 1977 |
[Ftorafur concentration in the blood and urine of oncological patients].
Topics: Biopharmaceutics; Biotransformation; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Flu | 1977 |
[A combined immuno-chemotherapy with futraful and picibanil for advanced cancer (author's transl)].
Topics: Aged; Biological Products; Drug Therapy, Combination; Female; Fluorouracil; Humans; Intestinal Neopl | 1977 |
Intermittent high single-dose ftorafur: phase I clinical trial with a pharmacologic-toxicity correlation.
Topics: Adult; Aged; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms | 1977 |
[Chemoimmunotherapy with BCG and FT 207 (author's transl)].
Topics: Adult; Aged; BCG Vaccine; Erythrocyte Count; Female; Fluorouracil; Humans; Lymphocytes; Male; Middle | 1977 |
[Effect of ftorafur and 5-fluorouracil on the chromosomes of human tumor cell cultures].
Topics: Cells, Cultured; Chromosome Deletion; Chromosomes, Human; Colonic Neoplasms; Fluorouracil; Humans; K | 1979 |
5-Fluorouracil concentrations in human plasma following R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) administration.
Topics: Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Tegafur; Time Factors | 1979 |
Drugs that make cancer retreat.
Topics: Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard | 1976 |
[Study of chemotherapy in the field of internal medicine--clinical experience with SF-SP].
Topics: Administration, Oral; Aged; Breast Neoplasms; Colonic Neoplasms; Delayed-Action Preparations; Drug A | 1986 |
[Report on nationwide pooled data and cohort investigation in UFT phase II study].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Sche | 1987 |
[Study on the preoperative adjuvant therapy of cancer--relation between serum and tumor tissue levels of UFT and OK-432 after administration, and skin reactions to Su-polysaccharide (Su-Ps)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Products; | 1987 |
[Effects of OK-432 on UFT activation].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Products; | 1988 |
Report on nationwide pooled data and cohort investigation in UFT phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Compounding; Drug Evaluation; Humans; Neoplasms | 1988 |